In Depth 6 Feb 2018 CRISPR/Cas9: Could the Gene Editing Technology be the Future of Drug Discovery? The emergence of CRISPR/Cas9 technologies has enabled almost unlimited gene editing opportunities. Not only could it be used as a therapeutic tool, the genome editing tool could kickstart a revolution in drug discovery. To date, much of the attention on CRISPR/Cas9, which stands for clustered regularly interspaced short palindromic repeats, has revolved around its potential as […] February 6, 2018 - 9 minutesmins - By Melanie De Almeida Share WhatsApp Twitter Linkedin Email
News and Trends 15 Sep 2017 Bayer Launches Plant Microbiome Biotech with a Huge €84M Series A Bayer and Ginkgo Bioworks are launching a new company that will develop new technologies for sustainable agriculture by engineering the plant microbiome. With the microbiome already gaining traction in the therapeutics field, Bayer has decided to take it to agriculture. In partnership with US synthetic biology upstart Ginkgo Bioworks, the German giant is creating a new […] September 15, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
More News! 24 Jul 2017 Bayer and Evotec Extend their Endometriosis Partnership Bayer and Evotec have decided to extend their partnership for the development of endometriosis drugs now that their second candidate has made it to Phase I. Bayer and Evotec have announced today that a second compound derived from their endometriosis partnership has made it to clinical trials. The team has decided to extend the partnership […] July 24, 2017 - 1 minutemin - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 20 Jun 2017 Novartis Tops Ophthalmology Blockbuster Eylea in Phase III Trials Bayer’s and Regeneron’s blockbuster Eylea could be facing serious competition, as Novartis boasts with positive Phase III results for AMD. Novartis has been struggling on the age-related macular degeneration (AMD) market since its Roche-partnered VEGF-A inhibitor Lucentis was outperformed by Eylea from Bayer and Regeneron, which required a less-frequent dosing schedule and was placed at a lower […] June 20, 2017 - 2 minutesmins - By Melanie De Almeida Share WhatsApp Twitter Linkedin Email
News and Trends 15 Jun 2017 Where to Find the Perfect Mix of International and German Biotechs? Berlin! Germany’s capital city Berlin is the perfect meeting place for international and German biotech companies. See here why the city has become a hotspot for life sciences research institutions and businesses! “Berlin! Berlin! We’re going to Berlin!” It might be a phrase usually sung by football fans, but maybe it’s time to have it chanted by other […] June 15, 2017 - 6 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
News and Trends 16 Mar 2017 What’s Berlin’s Secret to Success in Biotech & Digital Health? Berlin is a creative crossroads not just for arts but also life science. A variety of players in academia, industry, and startups make the ecosystem blossom. To those who know Berlin as a creative hub, it might come as a surprise that life science is one of the city’s industrial pillars. The German capital region […] March 16, 2017 - 8 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
Best in Biotech 8 Mar 2017 Which European Blockbusters Topped the Charts in 2016? Blockbuster drugs are raking in billions each year in sales. Let’s have a look at the top 7 European best-seller drugs of 2016 and what their competition has to say. Not surprisingly, the top 3 best-selling drugs in Europe are biologicals, which are revolutionizing the treatment possibilities for a range of conditions, from cancer to chronic diseases. But with the increasing […] March 8, 2017 - 4 minutesmins - By Melanie De Almeida Share WhatsApp Twitter Linkedin Email
News and Trends 26 Dec 2016 The Largest Deals, Fundraising and Exits of 2016 in European Biotech Curious about which technologies have attracted the most cash in biotech finance this year? Here’s a list of the most impressive cash movements of 2016 in Europe. Believe it or not, 2016 has been the worst year for biotech finance in a decade. The political scene has become unfavorable for British biotech after Brexit, and the uncertainty raised by […] December 26, 2016 - 5 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 14 Dec 2016 UPDATE: Bayer seals deal with Monsanto in Dark Side slide Bloomberg reports that Bayer has increased its bid once more to acquire the world’s least ethical company in order to solidify its position in agrochemicals. Bayer appears hell-bent on a Faustian bargain with Monsanto: the German chemical company has just thrown more money at America’s fourth most hated company in the hope of acquiring it. Despite its […] December 14, 2016 - 3 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
News and Trends 13 Dec 2016 European Pharma closes 2016 by launching new Biotech Startups Big pharma is already head on starting 2017 with a bang. Pfizer and Bayer are launching US-based startups in oncolytic virus and stem cell therapies. Pharma is wrapping up 2016 by investing in a pair of new ventures. Bayer and Versant have invested $225M to launch BlueRock Therapeutics, which will focus on CNS and cardiovascular diseases. This comes […] December 13, 2016 - 2 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
News and Trends 20 Oct 2016 German Record-deal Antiviral drug Succeeds in Phase III AiCuris’ Letermovir succeeds in Phase III after being licensed to MSD in a record €442.5M deal. It acts on a novel CMV target to treat bone marrow transplant infections. AiCuris is a spin-out company from Bayer, Germany’s biggest Pharma, that focuses on developing drugs for infectious diseases. The company licensed its candidate Letermovir (AIC246) to MSD (Merck & co.) in 2012, making it the […] October 20, 2016 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 20 Oct 2016 CRISPR Thx’ surprisingly low IPO… why are Investors Discouraged? Troubled waters in the CRISPR field: CRISPR Therapeutics’ IPO hits an unexpectedly low price. It seems that the investors are starting to switch from hype to uncertainty, but why now? CRISPR Therapeutics has just announced the results of a surprisingly low IPO: €51M ($56M), way lower than its €80M target. Its competitors in the therapeutics CRISPR field, Editas […] October 20, 2016 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email